论文部分内容阅读
目的评价利奈唑胺治疗中性粒细胞减少患者并发革兰阳性菌感染的临床疗效与安全性。方法选择62例中性粒细胞减少并发革兰阳性菌感染的恶性肿瘤患者,给予所有患者静脉滴注利奈唑胺600mg、1次/12h,根据治疗情况连续使用7～21d;观察治疗疗效以及患者的不良反应。结果在使用利奈唑胺治疗后,患者临床治愈43例,有效12例,进步2例,无效5例,总有效率为88.71%,药物不良反应总发生率为11.29%。结论利奈唑胺治疗恶性肿瘤患者中性粒细胞减少并发革兰阳性菌感染临床疗效确切,不良反应少。
Objective To evaluate the clinical efficacy and safety of linezolid in the treatment of Gram-positive bacterial infections in patients with neutropenia. Methods Sixty-two patients with malignant neoplasms infected with Gram-positive bacteria were enrolled in this study. All patients received linezolid 600 mg once a day for 12 to 21 days. The treatment was continued for 7 to 21 days. Adverse reactions. Results After treatment with linezolid, 43 patients were clinically cured, 12 were effective, 2 were improved, 5 were ineffective, with a total effective rate of 88.71% and a total adverse drug reaction rate of 11.29%. Conclusion linezolid treatment of malignant neoplasms patients with Gram-positive bacterial infection clinical efficacy and less adverse reactions.